MDCT上肝脾体积评估用于肝纤维化分期
研究分析624例患者MDCT肝脾体积,与病理纤维化分期对照。肝段体积比(LSVR)和脾总体积随纤维化分期增加,鉴别≥F3的AUC分别为0.863和0.890,联合为0.947;总肝体积预测价值差(AUC 0.506)。
要点
- LSVR和脾总体积随纤维化分期增加,总肝体积无此趋势。
- 鉴别≥F3纤维化,LSVR联合脾体积AUC达0.947。
- CT体积标志物可回顾性用于常规扫描,无需额外检查。
核心结论
- 肝段体积相对变化和脾总体积可用于无创肝纤维化分期,总肝体积预测价值差。
研究设计与样本
- 回顾性分析624例患者(平均48.8岁,男311/女313)MDCT肝脾体积,与病理纤维化分期(F0=374,F1=48,F2=40,F3=65,F4=97)对照;肝硬化前分期(METAVIR F1-F3)基于MDCT前1年内肝活检。
关键影像表现/征象
- LSVR和脾总体积随纤维化分期增加:F0为0.26±0.06和215.1±88.5 mm3,F1为0.25±0.08和294.8±153.4 mm3,F2为0.331±0.12和291.6±197.1 mm3,F3为0.39±0.15和509.6±402.6 mm3,F4为0.56±0.30和790.7±450.3 mm3。
- 总肝体积区分能力差:F0为1674±320 mm3,F4为1631±691 mm3。
诊断标准与关键数值
- LSVR定义为Couinaud I-III段体积除以IV-VIII段体积。
- 鉴别≥F3纤维化,LSVR的AUC为0.863,总肝体积为0.506,脾体积为0.890,LSVR联合脾体积为0.947。
临床应用与阅片要点
- CT体积标志物可回顾性用于其他指征的常规扫描,不同于肝活检或弹性成像。
- 肝脾体积评估用于纤维化分期与弹性成像相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate hepatosplenic volumetry at MDCT for non-invasive prediction of hepatic fibrosis.
METHODS: Hepatosplenic volume analysis in 624 patients (mean age, 48.8 years; 311 M/313 F) at MDCT was performed using dedicated software and compared against pathological fibrosis stage (F0 = 374; F1 = 48; F2 = 40; F3 = 65; F4 = 97). The liver segmental volume ratio (LSVR) was defined by Couinaud segments I-III over segments IV-VIII. All pre-cirrhotic fibrosis stages (METAVIR F1-F3) were based on liver biopsy within 1 year of MDCT.
RESULTS: LSVR and total splenic volumes increased with stage of fibrosis, with mean(±SD) values of: F0: 0.26 ± 0.06 and 215.1 ± 88.5 mm3; F1: 0.25 ± 0.08 and 294.8 ± 153.4 mm3; F2: 0.331 ± 0.12 and 291.6 ± 197.1 mm3; F3: 0.39 ± 0.15 and 509.6 ± 402.6 mm3; F4: 0.56 ± 0.30 and 790.7 ± 450.3 mm3, respectively. Total hepatic volumes showed poor discrimination (F0: 1674 ± 320 mm3; F4: 1631 ± 691 mm3). For discriminating advanced fibrosis (≥F3), the ROC AUC values for LSVR, total liver volume, splenic volume and LSVR/spleen combined were 0.863, 0.506, 0.890 and 0.947, respectively.
CONCLUSION: Relative changes in segmental liver volumes and total splenic volume allow for non-invasive staging of hepatic fibrosis, whereas total liver volume is a poor predictor. Unlike liver biopsy or elastography, these CT volumetric biomarkers can be obtained retrospectively on routine scans obtained for other indications.
KEY POINTS: • Regional changes in hepatic volume (LSVR) correlate well with degree of fibrosis. • Total liver volume is a very poor predictor of underlying fibrosis. • Total splenic volume is associated with the degree of hepatic fibrosis. • Hepatosplenic volume assessment is comparable to elastography for staging fibrosis. • Unlike elastography, volumetric analysis can be performed retrospectively.
引用
- Pickhardt PJ, Malecki K, Hunt OF, et al. Hepatosplenic volumetric assessment at MDCT for staging liver fibrosis. Eur Radiol. 2016. PMID: 27858212. doi:10.1007/s00330-016-4648-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。